How does the severity of coronavirus compare to the seasonal flu?

While most coronavirus cases are mild, similar to a cold or flu, it appears to have a higher case fatality ratio than seasonal flu. Although deaths primarily affect the elderly and those with pre-existing conditions, healthy individuals can also experience severe illness or die from coronavirus.

What is the R0 (basic reproduction number) for coronavirus?

The R0 for coronavirus is estimated to be in the range of 2 to 4, similar to influenza. Dr. Adalja emphasizes that R0 is not a fixed intrinsic feature but an average that depends on individual behavior and environment, and he groups viruses with R0s in this range together.

How does coronavirus spread, and can it survive on surfaces?

The primary mode of transmission is through respiratory droplets from coughs and sneezes, falling within about six feet. While coronaviruses can survive on surfaces for some time (potentially hours to a day), they are not as hardy as some other viruses and are easily deactivated by standard household cleaners.

What does 'flattening the curve' mean in the context of a pandemic?

Flattening the curve refers to spreading out the number of new cases over a longer period to prevent overwhelming healthcare systems. This is achieved through measures like social distancing, which reduces the intensity of spread, making it easier to manage limited resources like hospital beds.

Should I be worried about contracting coronavirus from packages shipped from abroad?

Dr. Adalja believes there is no significant risk of contracting the virus from ordinary products shipped internationally, even if they originated from an infected area. The virus does not typically survive long enough on these surfaces, and the primary transmission is through respiratory droplets.

What are the main risk factors for severe illness from coronavirus?

Beyond advancing age, risk factors include pre-existing conditions such as heart disease, lung disease, cancer, compromised immune systems, diabetes, and kidney disease. Men also appear to be disproportionately affected by more severe illness compared to women.

What is the projected timeline for a COVID-19 vaccine and effective antiviral treatments?

A vaccine is optimistically expected within 12-18 months due to rigorous safety testing. Effective antiviral treatments, potentially repurposed drugs like Remdesivir or Chloroquine, may become available sooner, possibly within several months after clinical trial data is analyzed.

When will widespread and easy testing for coronavirus be available?

While testing roadblocks are decreasing, widespread on-site testing in hospitals and readily available home testing kits are likely still several months away. The biggest mismanagement of the outbreak has been the lack of diagnostic testing capacity.

Will the spread of coronavirus diminish during the summer months?

Evidence from other seasonal coronaviruses suggests transmission may decrease in temperate climates during the summer. However, the virus might resurge in the fall, and the Southern Hemisphere will be entering its winter, potentially increasing spread there.

Is this pandemic a dress rehearsal for something potentially worse?

Dr. Adalja views this pandemic as a dress rehearsal for more catastrophic potential threats, such as an avian flu virus with high mortality and efficient human-to-human transmission. He emphasizes the importance of learning from this event to improve preparedness for future, possibly more severe, outbreaks.

What steps should individuals and institutions take to prevent future pandemics?

Key changes include improving surveillance for novel viruses, regulating live animal markets to prevent zoonotic spillover, developing broad-spectrum antivirals and vaccines proactively, and treating pandemic preparedness as a national security issue.

Key Moments

Early Thoughts On a Pandemic: A Conversation with Amesh Adalja (Episode #191)

Sam Harris

Science & Technology3 min read67 min video

Mar 12, 2020|240,444 views|2,671|796

sam harris sam harris podcast waking up podcast waking up waking up with sam harris sam harris waking up waking up sam harris sam harris jordan peterson sam harris joe rogan author neuroscientist philosopher

Save to Pod

Key Moments

TL;DR

Expert discusses COVID-19, emphasizing it's a dress rehearsal for worse pandemics, not the worst-case scenario.

Key Insights

The estimated case fatality rate for COVID-19 may be around 0.6%, significantly lower than initial high predictions but still higher than seasonal flu.

COVID-19 presents a spectrum of illness, with mild cases often indistinguishable from a cold, aiding its transmission.

Children may experience milder symptoms due to less robust immune responses or potential cross-immunity from prior coronavirus exposures.

The R0 (contagiousness factor) for COVID-19 is comparable to the flu, and social distancing aims to flatten the epidemic curve by spreading cases over time.

While effective treatments and a vaccine are months away, repurposed antivirals like Remdesivir and Chloroquine are being investigated.

The current pandemic should be viewed as a 'dress rehearsal' for potentially more severe future pandemics, highlighting the need for better preparedness.

ASSESSING THE SEVERITY AND FATALITY RATE

Dr. Amesh Adalja estimates the case fatality rate (CFR) for COVID-19 to be around 0.6%, with a range slightly above seasonal flu (0.1%), but considerably lower than initial 1-3% predictions. This estimate is largely based on data from South Korea, which has conducted extensive testing. The severity can be influenced by factors like age and pre-existing conditions, though healthy individuals can also be severely affected. The discrepancy in CFR estimates is partly due to a 'severity bias' where milder cases may go unreported or untested.

TRANSMISSION DYNAMICS AND SYMPTOM SPECTRUM

COVID-19 is primarily a respiratory virus spread through droplets from coughs and sneezes, and to a lesser extent, contaminated surfaces. The virus exhibits a wide spectrum of illness, from asymptomatic or mild cold-like symptoms to severe respiratory distress. This range, particularly the mild cases, facilitates undetected community spread. Children may experience milder symptoms, possibly due to immature immune systems or acquired cross-immunity from other seasonal coronaviruses, though their role in transmission is still under investigation.

THE IMPORTANCE OF SOCIAL DISTANCING AND FLATTENING THE CURVE

The concept of 'flattening the curve' aims to spread out the peak of infections over a longer period. This strategy is crucial for preventing healthcare systems from being overwhelmed by reducing the intensity of spread. Measures like working from home, canceling non-essential social gatherings, and avoiding crowded spaces are recommended. While individual risk assessment is important, collective social distancing is vital for managing community transmission and ensuring healthcare capacity.

TREATMENT AND VACCINE DEVELOPMENT TIMELINES

The development of effective treatments and a vaccine is ongoing. Antiviral treatments, such as repurposed drugs like Remdesivir and Chloroquine, are in clinical trials, with potential results expected in the coming months. Vaccine development is a longer process, with the most optimistic timeline for availability being 12 to 18 months, due to extensive safety testing required. Unlike the flu, a universal coronavirus vaccine might be achievable, potentially offering longer-lasting immunity.

SEASONALITY AND FUTURE PANDEMIC PREPAREDNESS

Similar to other seasonal coronaviruses, COVID-19 is expected to see reduced transmission during summer months, followed by a potential resurgence in the fall. This seasonality is influenced by both behavioral changes and the virus's interaction with environmental factors. Dr. Adalja emphasizes that the current pandemic serves as a critical 'dress rehearsal' for potentially more catastrophic future events, such as a highly lethal avian flu. This underscores the need for robust pandemic preparedness, improved surveillance, and proactive measures against emerging infectious diseases.

PREVENTATIVE MEASURES AND PUBLIC HEALTH ADVICE

Individuals are advised to practice good hygiene, similar to precautions taken during flu season. Seeking medical care should be a lower threshold for high-risk individuals, while the majority with mild symptoms can manage at home. Resources like the CDC, local health departments, and academic institutions (e.g., Johns Hopkins Center for Health Security, CIDRAP) are recommended for reliable information. Avoiding panic and ensuring healthcare systems are not overwhelmed by unnecessary visits are key public health goals.

Mentioned in This Episode

●Companies

●Organizations

●Books

●Drugs & Medications

●Concepts

●People Referenced

Common Questions

Dr. Adalja's best estimate, primarily based on South Korean data, places the upper bound of the case fatality rate at 0.6%, which is six times that of seasonal flu but significantly lower than some earlier predictions of 3% or more. This figure accounts for potential severity bias in testing.

Topics

Risk Assessment Health & Longevity Science & Mathematics Society & Philosophy Public Health Policy Pandemic Preparedness Case Fatality Rate Infectious Disease Transmission Viral Seasonality Medical Interventions

Mentioned in this video

People

Nicholas Christakis

Mentioned as the guest on a previous podcast episode about coronavirus, serving as a point of comparison for the current discussion.

Bill de Blasio

Mayor of New York City, whose statement about the virus degrading quickly on surfaces was contrasted with scientific understanding.

Amesh Adalja

An infectious disease specialist and critical care physician from Johns Hopkins University, providing expertise on pandemic preparedness.

Typhoid Mary

An example of an individual with a high R0 for Salmonella typhi, illustrating how individual behavior can impact transmission.

Concepts

Salmonella typhi

Mentioned as an example of a pathogen that can have a very high R0 due to specific carriers, like Typhoid Mary.

Ebola

Used as a point of comparison for both drug repurposing (Remdesivir trial) and political politicization of outbreaks.

Global Catastrophic Biological Risks

A volume edited by Dr. Adalja, indicating his expertise in high-impact biological threats.

Seasonal Flu

Used as a benchmark for comparison regarding case fatality rates and contagiousness, with coronavirus showing a higher CFR.

Norovirus

Mentioned as a comparison to coronaviruses, highlighting its hardiness on surfaces, unlike enveloped viruses.

Influenza

A common respiratory illness used as a baseline to compare the severity and contagiousness of the novel coronavirus.

Avian Flu

Mentioned as a more dangerous potential threat with high mortality rates (up to 60%) if it were to become efficiently transmissible between humans.

Tetanus

Used as an example of a disease that is not transmissible between humans, highlighting a contrast with respiratory viruses.

Locations

Singapore

Mentioned as a country that implemented variations of China's containment model.

China

As the origin of the outbreak and a source of goods shipped internationally, also discussed in relation to its public health response.

Westchester County

A location in New York State where social distancing measures were being implemented.

South Korea

Cited for its extensive per capita testing for coronavirus, providing the basis for Dr. Adalja's case fatality rate estimate.

Taiwan

Mentioned as a location that implemented variations of China's containment model.

Hong Kong

Mentioned as a location that implemented variations of China's containment model.

Organizations

Johns Hopkins Center for Health Security

Dr. Adalja's think-tank focused on infectious disease emergencies, founded by the eradicater of smallpox, D.A. Henderson.

The Lancet

A medical journal that previously reported a higher case fatality rate for coronavirus than Dr. Adalja's estimate.

Center for Infectious Disease Research and Policy

Associated with the University of Minnesota, this center is a recommended source for infectious disease news and policy.

Fox News

Mentioned in the context of political polarization, where denial of the virus's severity is perceived to be prevalent.

World Health Organization

A recommended source for reliable information on the coronavirus outbreak.

Johns Hopkins University

The institution where Dr. Adalja is affiliated and a primary resource for coronavirus tracking and information.

The Gates Foundation

Investing in home testing for coronavirus, similar to efforts for flu testing.

Companies

Apple

Mentioned as a source of a computer shipped from Shanghai, used as an example to discuss the risk of transmission via mail.

Gilead

The manufacturer of Remdesivir, mentioned in the context of its potential for rapid production and early availability if effective.

Media

Stat News

A premier science reporting outlet, recommended for reliable coronavirus information.

Books

Health Security

A journal edited by Dr. Adalja, focusing on global catastrophic biological risks.

Handbook of Bioterrorism and Disaster Medicine

A publication co-authored by Dr. Adalja.

Drugs & Medications

Chloroquine

A malaria drug being repurposed, showing potential antiviral effects in vitro, and available for off-label prescription.

Measles

Used as an example of a highly contagious disease with a high R0 (around 15).

Remdesivir

An antiviral used in Ebola trials that showed activity against coronaviruses and is currently in Phase 2 clinical trials for COVID-19.

Found this useful? Build your knowledge library

Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.

Try Summify free